{"id":"im862","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IM862 is a synthetic peptide that acts as an immune stimulant, primarily working through IL-2 signaling to enhance T-cell proliferation and natural killer cell activity. It was developed to boost anti-tumor immune responses and has been investigated for its ability to potentiate immune-mediated tumor control in cancer patients.","oneSentence":"IM862 is an immunomodulatory agent that enhances immune function through interleukin-2 (IL-2) pathway activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:52.995Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic renal cell carcinoma"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT00003773","phase":"PHASE1","title":"IM-862 in Treating Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"University of Southern California","startDate":"1999-02","conditions":"Ovarian Cancer","enrollment":43},{"nctId":"NCT00006037","phase":"PHASE2","title":"Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"1999-11","conditions":"Colorectal Cancer","enrollment":18},{"nctId":"NCT00017303","phase":"PHASE2","title":"Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer","status":"UNKNOWN","sponsor":"Cytran","startDate":"2001-01","conditions":"Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":""},{"nctId":"NCT00002445","phase":"PHASE3","title":"Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients","status":"COMPLETED","sponsor":"Cytran","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IM862","genericName":"IM862","companyName":"Cytran","companyId":"cytran","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IM862 is an immunomodulatory agent that enhances immune function through interleukin-2 (IL-2) pathway activation. Used for Metastatic renal cell carcinoma, Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}